Surgery vs. GLP-1 Drugs: Which Gets More Kidney Failure Patients to Transplant?
A decision model found sleeve gastrectomy tripled kidney transplant access compared to single GLP-1 drugs, but dual GLP-1/GIP agonists offered a substantial non-surgical alternative.
Quick Facts
What This Study Found
Using a Markov decision model, researchers compared three weight loss strategies for morbidly obese patients with end-stage kidney disease who need to reach BMI ≤35 to qualify for kidney transplant. At 5 years, sleeve gastrectomy got the most patients to transplant (14.74%), followed by dual GLP-1/GIP receptor agonists like tirzepatide (9.06%), and single GLP-1 agonists (4.83%).
Sleeve gastrectomy produced faster weight loss, with 27.49% of patients reaching the BMI target by 6 months. Surgery also showed a survival advantage, especially in patients starting at higher BMIs.
However, dual GLP-1/GIP agonists still got a substantial number of patients to transplant and represent a viable non-surgical alternative, particularly for patients who cannot undergo or prefer to avoid surgery.
Key Numbers
14.74% transplant rate with surgery at 5 years · 9.06% with dual GLP-1/GIP agonist · 4.83% with single GLP-1 agonist · 27.49% reached BMI ≤35 by 6 months with surgery
How They Did This
Markov state transition model simulating outcomes for morbidly obese patients with end-stage renal disease under three weight loss interventions. Patients transitioned between health states based on weight loss trajectories, transplant eligibility (BMI ≤35 kg/m²), and survival. Model parameters were derived from published literature on each intervention.
Why This Research Matters
Obese patients with kidney failure face a cruel catch-22: they need a transplant to survive, but many transplant programs require BMI below 35 first. This study quantifies how different weight loss strategies affect the odds of actually reaching that threshold and getting a kidney. It shows surgery is fastest, but the newer dual-agonist drugs offer a meaningful pharmaceutical alternative — especially important for patients too sick for elective surgery.
The Bigger Picture
This study sits at the intersection of two major trends — the explosion of GLP-1-based weight loss drugs and the growing recognition that obesity is a barrier to life-saving organ transplants. As dual and triple agonist drugs become available, they may increasingly compete with bariatric surgery as a pathway to transplant eligibility, especially for patients who are poor surgical candidates.
What This Study Doesn't Tell Us
This is a mathematical model, not a clinical trial — results depend entirely on the assumptions and input parameters used. Real-world outcomes may differ due to patient adherence, complications, drug availability, and individual variation in weight loss response. The model does not account for weight regain after initial loss or complications specific to dialysis patients undergoing surgery.
Questions This Raises
- ?Would triple agonists (GLP-1/GIP/glucagon) close the gap with surgery even further?
- ?How does weight regain after stopping GLP-1 drugs affect long-term transplant eligibility?
- ?Should transplant programs lower their BMI thresholds given effective pharmacological weight loss options?
Trust & Context
- Key Stat:
- 14.74% vs. 4.83% At 5 years, sleeve gastrectomy got roughly three times as many morbidly obese kidney failure patients to transplant compared to single GLP-1 receptor agonists.
- Evidence Grade:
- This is a Markov decision analysis — a mathematical model — not a clinical trial. While useful for comparing strategies, its conclusions depend on assumed parameters from published literature and cannot account for real-world complexity. Evidence certainty is low to moderate.
- Study Age:
- Published in 2025, this study reflects the current treatment landscape including newer dual GLP-1/GIP agonists. Highly relevant as these drugs become more widely prescribed for obese patients with comorbidities.
- Original Title:
- Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to improve access to kidney transplantation in patients with end-stage renal disease and obesity: A decision analysis.
- Published In:
- American journal of surgery, 250, 116475 (2025)
- Authors:
- Di Napoli, Marissa, Rouhi, Armaun D, Baimas-George, Maria, Dumon, Kristoffel, Castle, Rose, Kennealey, Peter, Nydam, Trevor, Choudhury, Rashikh
- Database ID:
- RPEP-10708
Evidence Hierarchy
Frequently Asked Questions
Why can't obese patients get a kidney transplant?
Many transplant programs set a BMI cutoff (often ≤35 kg/m²) because severe obesity increases surgical complications, graft failure, and post-transplant mortality. Patients must lose enough weight to meet this threshold before being listed for a kidney.
Can GLP-1 drugs replace surgery for getting patients to transplant?
Not entirely, based on this model. Surgery got nearly three times more patients to transplant than single GLP-1 drugs. However, dual GLP-1/GIP agonists performed meaningfully better than single agents and offer a viable option for patients who can't have surgery or prefer a non-surgical approach.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-10708APA
Di Napoli, Marissa; Rouhi, Armaun D; Baimas-George, Maria; Dumon, Kristoffel; Castle, Rose; Kennealey, Peter; Nydam, Trevor; Choudhury, Rashikh. (2025). Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to improve access to kidney transplantation in patients with end-stage renal disease and obesity: A decision analysis.. American journal of surgery, 250, 116475. https://doi.org/10.1016/j.amjsurg.2025.116475
MLA
Di Napoli, Marissa, et al. "Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to improve access to kidney transplantation in patients with end-stage renal disease and obesity: A decision analysis.." American journal of surgery, 2025. https://doi.org/10.1016/j.amjsurg.2025.116475
RethinkPeptides
RethinkPeptides Research Database. "Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to..." RPEP-10708. Retrieved from https://rethinkpeptides.com/research/di-2025-sleeve-gastrectomy-versus-dual
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.